Download presentation
Presentation is loading. Please wait.
Published byAnabel Wiggins Modified over 9 years ago
1
Zack Perconti
2
Recent News Faheem Hasnain recently appointed to Board of Directors Management experience at several major Biotech companies, including GlaxoSmithKline Silenor available for prescription on Sept. 7 th, 2010 “Full-scale field promotion” of Silenor began Sept 20 th, 2010 Massive advertising initiative undertaken in conjunction with Procter & Gamble.
3
Silenor Silenor’s release is the first major test of market success for Somaxon However, Silenor faces stiff competition Ambien CR and Lunesta Product fills expensive niche role Comparison with Dopexin, generic form of Silenor
4
Outlook Partnership with Procter & Gamble could be sign of takeover However, terms of Deal weighted heavily in P&G’s favor Large market does exist for Silenor Fills niche Lower dosage than generic Fewer side effects than major competitors Stock price could dramatically increase if Silenor begins to establish market share.
5
Pros/Cons Pros Potential for growth Relatively new company – potential for buyout and merger with larger company Procter & Gamble partnership Silenor is prescription, but not a controlled substance Massive marketing initiative designed to establish market share. Cons Small company – low market cap Extremely volatile – 52 week range; $0.90-$10.60 “Eggs in one basket” Company focused largely on one product, Silenor OTC, generic competition Initial losses expected from advertising required to gain market share. Stock has dropped nearly 60% since March 2010, around the date of initial announcement of Silenor Success closely tied to that of Procter & Gamble & Silenor product. Associate Verdict: Extremely Risky, but potential for huge profits
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.